Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Orgenesis's share price for the quarter that ended in Dec. 2023 was $0.5007. Orgenesis's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 31.88 Mil. Therefore, Orgenesis's market cap for the quarter that ended in Dec. 2023 was $15.96 Mil.
Orgenesis's quarterly market cap
declined
from Jun. 2023 ($39.57 Mil) to Sep. 2023 ($18.89 Mil) and
declined
from Sep. 2023 ($18.89 Mil) to Dec. 2023 ($15.96 Mil).
Orgenesis's annual market cap
declined
from Dec. 2021 ($69.93 Mil) to Dec. 2022 ($49.81 Mil) and
declined
from Dec. 2022 ($49.81 Mil) to Dec. 2023 ($15.96 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Orgenesis's Enterprise Value for Today is $39.37 Mil.
Orgenesis Market Cap Historical Data
The historical data trend for Orgenesis's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Orgenesis Annual Data
Trend
Nov14
Nov15
Nov16
Nov17
Nov18
Dec19
Dec20
Dec21
Dec22
Dec23
Market Cap
75.22
109.00
69.93
49.81
15.96
Orgenesis Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Market Cap
49.81
32.88
39.57
18.89
15.96
Competitive Comparison
For the Biotechnology subindustry, Orgenesis's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orgenesis Market Cap Distribution
For the Biotechnology industry and Healthcare sector, Orgenesis's Market Cap distribution charts can be found below:
* The bar in red indicates where Orgenesis's Market Cap falls into.
Orgenesis Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Orgenesis's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orgenesis (NAS:ORGS) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Orgenesis Market Cap Related Terms
Thank you for viewing the detailed overview of Orgenesis's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Morgenesis and Therapies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ORGS has been successfully added to your 